You are here: Industry Insights > Eli Lilly

News List

INEX Innovate's iGene Laboratory announces new personalised medicine genotyping analysis project with Eli Lilly and Company's research unit Lilly Centre for Clinical Pharmacology prnasia
November 19, 2020
INEX Innovate's iGene Laboratory (iGene) announced today a project with Eli Lilly and Company's research unit Lilly Centre for Clinical Pharmacology (LCCP), which conducts early phase clinical trials in healthy participants and patients in Singapore.
Samsung Biologics signs Covid-19 therapy manufacturing deal with Lilly pharmaceutical-technology
November 18, 2020
South Korean pharma firm Samsung Biologics has entered a long-term agreement with Eli Lilly and Company to manufacture its investigational Covid-19 virus neutralising antibody, bamlanivimab.
FDA grants EUA for Lilly’s monoclonal antibody for Covid-19 treatment pharmaceutical-technology
November 11, 2020
The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Eli Lilly and Company’s monoclonal antibody, bamlanivimab (LY-CoV555) 700mg, to treat patients recently diagnosed with Covid-19.
AbCellera antibody gets US FDA EUA as monotherapy for COVID-19 treatment expresspharma
November 11, 2020
AbCellera’s partner, Eli Lilly and Company, will supply the US government with 300,000 doses of bamlanivimab for allocation to high-risk patients.
US to begin distribution of Bamlanivimab, COVID-19 antibody from Eli Lilly expresspharma
November 11, 2020
Bamlanivimab allocations to states and territories will be based on their number of hospitalised COVID-19 patients and the number of overall cases, informed government officials.
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine worldpharmanews
November 06, 2020
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 ...
Lilly, Incyte tout new baricitinib data in eczema pharmatimes
November 05, 2020
Eli Lilly and Incyte showcased new data for their JAK inhibitor baricitinib in eczema at the virtual European Academy of Dermatology and Venereology (EADV) congress on Saturday.
Lilly, U.S. Govt. Enter Supply Pact for Bamlanivimab COVID-19 Treatment contractpharma
October 29, 2020
Initial agreement is for 300,000 vials of the investigational neutralizing antibody with potential for purchase of an additional 650,000 vials.
Eli Lilly to acquire biotechnology company Disarm Therapeutics pharmaceutical-technology
October 19, 2020
Eli Lilly has entered a definitive agreement to acquire biotech firm Disarm Therapeutics for an upfront payment of $135m.
Fujifilm Diosynth to Manufacture Lilly COVID-19 Antibody contractpharma
October 15, 2020
Commercial manufacturing of the antibody therapy is expected to commence in April 2021.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page